Predict your next investment


See what CB Insights has to offer


Acquired | Acquired

About Saliency

Saliency enables pharmaceutical companies to leverage artificial intelligence in their R&D. The company's software aggregates data from multiple sites, labels efficiently by skilled physicians, runs deep learning code and deploys models in compliance with HIPAA.On January 6, 2021, Saliency was acquired by Bioclinica. The terms of the transaction were not disclosed.

Saliency Headquarter Location

Palo Alto, California,

United States


Latest Saliency News

AI-based image redaction guards trial patient privacy

Feb 1, 2021

By Jenni Spinner Bioclinica’s Image Redact AI tool enables trials to edit sensitive information from videos, photos and PDFs to ensure compliance and safeguard patient data Clinical technology provider Bioclinica has launched Image Redact AI, an artificial intelligence (AI) based technology that enables clinical trials to redact sensitive patient identifiers from photos, videos and PDFs. While in the past researchers have found it challenging to ensure videos fully comply with patient privacy requirements (risking the incurrence of costly penalties and downstream issues), Image Redact AI’s technology reportedly makes it possible to do, quickly and effectively. Bioclinica’s chief innovation officer Dan Gebow, PhD, told Outsourcing-Pharma that in addition to potential risk of having to pay for non-compliance of privacy requirements, failure to protect patient information could lead to damage to a sponsor’s reputation. “Bioclinica Image Redact AI safeguards sensitive clinical trial data by automatically redacting patient identifiers from videos, photos, and PDFs​,” he explained. “This solution leads the industry with its ability to pair a high level of AI-driven de-identification with the human oversight of an experienced quality control team; this combination helps ensure videos and photos comply with 21 CFR Part 11, EU GDPR, and other privacy regulations​." Gebow said before a video, photo or PDF is uploaded into the system, Image Redact AI prescreens images to verify file type and size, then quickly conducts the de-identification process to remove all sensitive patient information. Next, the company’s image quality control technicians perform a visual QC review. “This two-step process confirms complete de-identification before the image can be made available​,” he told us. While other products currently available purport to screen clinical patient images, these products unfortunately tend to fall short in fully protecting patient information. “For some research it is necessary to see parts of the face, such as the upper lip, forehead, or the color of the skin; in these instances, a sponsor’s only previous option was to perform the redaction themselves​,” Gebow said. “This manual process is error-prone and time-intensive, and it can consume valuable research dollars​.” The introduction of Image Redact AI comes after Bioclinica’s acquisition of Saliency, an AI specialist with technology designed to accelerate of image QC and interpretation to support rapid development of digital diagnostics and therapeutics. “After evaluating a variety of medical imaging AI platforms, we knew the Saliency platform was and is head and shoulders above others in the market as far as its ability to deliver value for our clients​,” Gebow related. “Our acquisition of Saliency empowers industry stakeholders with the absolute latest in medical imaging technology by delivering custom AI models faster and with more accuracy​.” The Image Redact AI platform uses proprietary algorithms to quickly build and train AI models from a small number of de-identified images; these newly created models can then be used to accurately and efficiently screen, redact, or interpret medical images to support a wide range of therapeutic areas. This capability will be embedded into Bioclinica’s imaging solutions in accordance with EU GDPR and other privacy regulations. “This advancement is one of many that our innovation team has in our pipeline to accelerate the pace of clinical trials, increase data integrity, and protect patient privacy​,” Gebow added. “We are looking forward to releasing these related enhancements to our fellow researchers over the coming months​.” Copyright - Unless otherwise stated all contents of this web site are © 2021 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Saliency

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Saliency is included in 1 Expert Collection, including Digital Health.


Digital Health

10,285 items

Companies using/incorporating digital tech into health, wellness, and life science offerings. Includes cos operating within the hc, consumer health, and life science industries + tech vendors catering to them. Excludes cos exclusively focused on fitness/sports & performance

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.